p.91 抽出テキスト

studies from 90 countries. Circulation 2016;134:441–50. https://doi.org/10.1161/ circulationaha.115.018912 308. Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol 2018;14:428–41. https://doi.org/10. 1038/s41581-018-0006-6 309. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb Cheryl R, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018;72: e53–90. https://doi.org/10.1161/hyp.0000000000000084 310. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 2019;73: 424–31. https://doi.org/10.1161/hypertensionaha.118.12191 311. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014;311:2216–24. https://doi.org/10.1001/jama.2014.5180 312. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015;385:1957–65. https://doi.org/10.1016/s0140-6736(14) 61942-5 313. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293–300. https://doi.org/10.1016/j.jacc.2006.07.059 314. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011;58:811–7. https://doi.org/10. 1161/hypertensionaha.111.179788 315. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921–6. https://doi.org/10.1016/s0140- 6736(08)60834-x 316. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811–20. https://doi.org/10.1016/j.jacc.2017.01.052 317. Käyser SC, Deinum J, de Grauw WJ, Schalk BWM, Bor HJHJ, Lenders JWM, et al. Prevalence of primary aldosteronism in primary care: a cross-sectional study. Br J Gen Pract 2018;68:e114–22. https://doi.org/10.3399/bjgp18X694589 318. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245–54. https://doi.org/10.1093/ eurheartj/eht534 319. Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, et al. Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension. High Blood Press Cardiovasc Prev 2020;27:547–60. https://doi.org/10. 1007/s40292-020-00415-9 320. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892–6. https://doi.org/10.1161/01.hyp.0000040261.30455.b6 321. Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, et al. Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension 2020;75: 650–9. https://doi.org/10.1161/hypertensionaha.119.14359 322. Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension 2022;79:178–86. https://doi.org/10.1161/hypertensionaha.121.18118 323. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4 324. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013;62: 331–6. https://doi.org/10.1161/hypertensionaha.113.01060 325. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981;141:1589–93. https://doi.org/ 10.1001/archinte.1981.00340130033011 326. Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol 2019; 74:2799–811. https://doi.org/10.1016/j.jacc.2019.09.057 327. Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM. Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism—the EMIRA study. J Clin Endocrinol Metab 2020;105:2060–7. https://doi.org/10.1210/clinem/dgaa080 328. Rossi GP, Bisogni V, Bacca AV, Bacca AV, Belfiore A, Cesari M, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens 2020;5:100029. https://doi.org/10.1016/j. ijchy.2020.100029 329. Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, et al. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens 2024;38:8–18. https://doi.org/10.1038/s41371-023-00875-1 330. Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 2014;129:1048–78. https://doi. org/10.1161/01.cir.0000442577.96802.8c 331. Faconti L, Morselli F, Sinha M, Chrysochou C, Chowienczyk PJ. Fibromuscular dysplasia and hypertension—a statement on behalf of the British and Irish Hypertension Society. J Hum Hypertens 2021;35:1051–3. https://doi.org/10.1038/s41371-020-00456-6 332. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2019;37:229–52. https://doi.org/10.1097/hjh.0000000000002019 333. Abrishami A, Khajehdehi A, Chung F. A systematic review of screening questionnaires for obstructive sleep apnea. Can J Anaesth 2010;57:423–38. https://doi.org/10.1007/ s12630-010-9280-x 334. Chai-Coetzer CL, Antic NA, Hamilton GS, McArdle N, Wong K, Yee BJ, et al. Physician decision making and clinical outcomes with laboratory polysomnography or limitedchannel sleep studies for obstructive sleep apnea: a randomized trial. Ann Intern Med 2017;166:332–40. https://doi.org/10.7326/m16-1301 335. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366:665–75. https://doi.org/10.1016/s0140-6736(05)67139-5 336. Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020;38:1443–56. https://doi.org/10.1097/hjh.0000000000002438 337. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999;141:619–24. https://doi.org/10.1530/eje.0. 1410619 338. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019;381:552–65. https://doi.org/10.1056/NEJMra1806651 339. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018;6:51–9. https://doi.org/10.1016/s2213- 8587(17)30367-4 340. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365:434–41. 341. Yang L, Sun J, Zhao M, Liang Y, Bovet P, Xi B. Elevated blood pressure in childhood and hypertension risk in adulthood: a systematic review and meta-analysis. J Hypertens 2020;38:2346–55. https://doi.org/10.1097/hjh.0000000000002550 342. Allen NB, Krefman AE, Labarthe D, Greenland P, Juonala M, Kähönen M, et al. Cardiovascular health trajectories from childhood through middle age and their association with subclinical atherosclerosis. JAMA Cardiol 2020;5:557–66. https://doi.org/10. 1001/jamacardio.2020.0140 343. de Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, et al. Hypertension in children and adolescents. Eur Heart J 2022;43:3290–301. https://doi.org/10.1093/ eurheartj/ehac328 344. Falkstedt D, Koupil I, Hemmingsson T. Blood pressure in late adolescence and early incidence of coronary heart disease and stroke in the Swedish 1969 conscription cohort. J Hypertens 2008;26:1313–20. https://doi.org/10.1097/HJH.0b013e3282ffb17e 345. Jacobs DR Jr, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood cardiovascular risk factors and adult cardiovascular events. N Engl J Med 2022;386: 1877–88. https://doi.org/10.1056/NEJMoa2109191 346. Oikonen M, Nuotio J, Magnussen CG, Viikari JSA, Taittonen L, Laitinen T, et al. Repeated blood pressure measurements in childhood in prediction of hypertension in adulthood. Hypertension 2016;67:41–7. https://doi.org/10.1161/hypertensionaha. 115.06395 347. Garcia-Lunar I, van der Ploeg HP, Fernández Alvira JM, van Nassau F, Castellano Vázquez JM, van der Beek AJ, et al. Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial. Eur Heart J 2022;43:3732–45. https://doi.org/10.1093/eurheartj/ehac378 348. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med 2021;385:1067–77. https://doi.org/10. 1056/NEJMoa2105675 349. He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:632–47. https://doi.org/10.1016/j.jacc.2019.11.055 350. Ma Y, He FJ, Sun Q, Yuan C, Kieneker LM, Curhan GC, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2022;386:252–63. https://doi.org/10.1056/NEJMoa2109794 351. Ma H, Xue Q, Wang X, Li X, Franco OH, Li Y, et al. Adding salt to foods and hazard of premature mortality. Eur Heart J 2022;43:2878–88. https://doi.org/10.1093/ eurheartj/ehac208 352. Huang L, Trieu K, Yoshimura S, M Woodward, N Campbell, D Lackland, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026